Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jinxin Fertility Completes Financing Led by Warburg and CNCB

publication date: Oct 9, 2018

Jinxin Fertility, a company providing assisted reproductive technology services, received a strategic investment led by Warburg Pincus and CNCB Investment, a CITIC unit. Jinxin ranks second in China in terms of number of reproductive procedures performed. The company has centers in Chengdu, Shenzhen and the US, the latter providing services that are not available in China. Sequoia Capital China and WuXi AppTec also participated in the investment, whose size was not disclosed. Jinxin Fertility is headquartered in Chengdu, Sichuan Province. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here